Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Author:
Edara Venkata ViswanadhORCID, Norwood Carson, Floyd Katharine, Lai Lilin, Davis-Gardner Meredith E.ORCID, Hudson William H., Mantus Grace, Nyhoff Lindsay E., Adelman Max W., Fineman Rebecca, Patel Shivan, Byram Rebecca, Gomes Dumingu Nipuni, Michael Garett, Abdullahi Hayatu, Beydoun Nour, Panganiban Bernadine, McNair Nina, Hellmeister Kieffer, Pitts Jamila, Winters Joy, Kleinhenz Jennifer, Usher Jacob, O’Keefe James B., Piantadosi AnneORCID, Waggoner Jesse J.ORCID, Babiker AhmedORCID, Stephens David S., Anderson Evan J., Edupuganti Srilatha, Rouphael Nadine, Ahmed RafiORCID, Wrammert JensORCID, Suthar Mehul S.ORCID
Abstract
SUMMARYThe emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.
Publisher
Cold Spring Harbor Laboratory
Reference31 articles.
1. Anand, S.P. , Prevost, J. , Nayrac, M. , Beaudoin-Bussieres, G. , Benlarbi, M. , Gasser, R. , Brassard, N. , Laumaea, A. , Gong, S.Y. , Bourassa, C. , et al. (2021). Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. bioRxiv. 2. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults;New England Journal of Medicine,2020 3. Babiker, A. , Bradley, H.L. , Stittleburg, V.D. , Ingersoll, J.M. , Key, A. , Kraft, C.S. , Waggoner, J.J. , and Piantadosi, A. (2020). Metagenomic Sequencing To Detect Respiratory Viruses in Persons under Investigation for COVID-19. J Clin Microbiol 59. 4. Dan, J.M. , Mateus, J. , Kato, Y. , Hastie, K.M. , Yu, E.D. , Faliti, C.E. , Grifoni, A. , Ramirez, S.I. , Haupt, S. , Frazier, A. , et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, NY) 371. 5. Edara, V.V. , Floyd, K. , Lai, L. , Gardner, M. , Hudson, W. , Piantadosi, A. , Waggoner, J.J. , Babiker, A. , Ahmed, R. , Xie, X. , et al. (2021). Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv, 2021.2002.2002.21250799.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|